未登录

G

Guangbo Kang

Tianjin University

H指数:19

被引数:1,108

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bacterial Armory: Engineering Dual Photosensitized Bacteria for a Triple-Modal Therapy on Tumors

细菌军械库：构建用于肿瘤三模态治疗的双光敏化细菌

IF12.1

2025-12-010

PRE

Noncanonical amino acid-aided synthesis of anti-PD-L1 bispecific nanobody for colon cancer immunotherapy

非经典氨基酸辅助的抗PD-L1双特异性纳米抗体合成及其在结肠癌免疫治疗中的应用

Communications Biology

IF5.1

2025-11-240

OAAI

Synthetic microbial consortia based on quorum-sensing for disease therapy

基于群体感应的合成微生物共培养物用于疾病治疗

Bioresources and Bioprocessing

IF5.1

2025-11-030

OAAI

An Engineered Probiotic Consortium Based on Quorum-Sensing for Colorectal Cancer Immunotherapy

一种基于群体感应的工程益生菌共生体用于结直肠癌免疫治疗

Advanced Science

IF14.1

2025-09-260

OAAI

Flexible Regulation of Optical Properties Based on Structure Size-Driven Intermolecular Interactions for Phototherapy

基于结构尺寸驱动的分子间相互作用对光疗光学特性的柔性调控

ADVANCED SCIENCE

IF14.1

2025-04-240

OAAI

Propionate-producing engineered probiotics ameliorated murine ulcerative colitis by restoring anti-inflammatory macrophage via the GPR43/HDAC1/IL-10 axis

BIOENGINEERING & TRANSLATIONAL MEDICINE

IF5.7

2024-05-271

OAAI

Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities

CLINICAL AND TRANSLATIONAL MEDICINE

IF6.8

2024-03-272

OAAI

Intermolecular Interaction Between BODIPY and TPE Enhances Phototherapy

ADVANCED OPTICAL MATERIALS

IF7.2

2024-03-031

PRE

A tailored series of engineered yeasts for the cell-dependent treatment of inflammatory bowel disease by rational butyrate supplementation

一系列定制的工程酵母，用于通过合理补充丁酸酯来细胞依赖性治疗炎症性肠病

IF11

2024-02-216

OAAI

A synthetic microbial consortium protects against obesity by regulating vitamin B6 metabolism

IF11

2024-01-254

OAAI

Affinity maturation of antibody fragments: A review encompassing the development from random approaches to computational rational optimization

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

IF8.5

2023-08-0110

OAAI

Synthetic bacterial therapies for intestinal diseases based on quorum-sensing circuits

BIOTECHNOLOGY ADVANCES

IF12.5

2023-07-019

OAAI

Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2023-02-0110

OAAI

Modeling spatial interaction networks of the gut microbiota

IF11

2022-08-0312

OAAI

Positive Interventional Effect of Engineered Butyrate-Producing Bacteria on Metabolic Disorders and Intestinal Flora Disruption in Obese Mice

MICROBIOLOGY SPECTRUM

IF3.8

2022-04-2727

OAAI

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-01-1854

OAAI

The Potential Role of Phytonutrients Flavonoids Influencing Gut Microbiota in the Prophylaxis and Treatment of Inflammatory Bowel Disease

FRONTIERS IN NUTRITION

IF5.1

2021-12-1441

OAAI

VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo

CANCER BIOLOGY & MEDICINE

IF8.4

2021-01-0115

OAAI

Comparative genomics analysis of Acinetobacter haemolyticus isolates from sputum samples of respiratory patients

IF3

2020-07-0115

PRE

Engineered butyrate-producing bacteria prevents high fat diet-induced obesity in mice

MICROBIAL CELL FACTORIES

IF4.9

2020-04-2548

OAAI